Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Evidence of advanced, non-resectable, and/or metastatic non-small cell lung cancer and at least one previous conventional treatment for advanced disease
Eastern cooperative Oncology Group (ECOG) performance status of 0 or 1
Measurable or evaluable disease, determined by World Health Organization (WHO) criteria using standard imaging modalities, including ultrasound, X-ray, CT and/or Magnetic Resonance Imaging (MRI). Bone scans and/or antibody scans are not to be used to determine the extent of the disease
Expected survival of ≥ 16 weeks
At least 18 years of age
Platelet count ≥ 100 x 10\*\*9/L
Absolute neutrophil count ≥ 2.0 x 10\*\*9/L
Aspartate aminotransferase (AST) ≤ 3 x upper limit of normal or \< 5 x upper limit of normal if liver metastases are present
Total bilirubin ≤ 2mg/dL
Serum creatinine ≤ 2mg/dL
Ability to provide written informed consent
You may not be if
Known brain metastases
Exposure to an investigational agent within 30 days prior to receiving the scout dose
Incomplete recovery from surgery or incomplete healing of an incision site or evidence of infection
Treatment with cytotoxic chemotherapy, radiation or immunosuppressive therapy within the 30 days (42 days for nitrosoureas and/or mitomycin C) of the scout infusion. Patients using inhaled corticosteroids are considered eligible for enrollment
Serious illnesses, i.e., active infections requiring antibiotics, bleeding disorders or other serious illnesses precluding the use of either 131I or sibrotuzumab
Women who are breast-feeding or pregnant
Men and women who were sexually active and are unwilling to utilize a medically acceptable method of contraception
Hypertrophic skin disease or autoimmune disease that possibly involves over-expression of fibroblast activation protein (FAP), which can be targeted by the antibody. These diseases include active inflammatory arthritis, cirrhosis, and keloids
Unstable angina pectoris. Patients prescribed medication to control their angina pectoris must have been on a fixed dose for at least 1 month prior to screening to be eligible for trial enrollment
Myocardial infarction within 3 months prior to screening
New York Heart Association (NYHA) Heart failure stage III or IV, or a left ventricular ejection fraction of ≤ 40 %
Impaired lung function, measured by a decrease in forced expiratory volume at one second (FEV1) to less than 50 % of the predicted normal value